To include your compound in the COVID-19 Resource Center, submit it here.

Zealand starts second Phase III of dasiglucagon for severe hypoglycemia

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) began a second Phase III trial to evaluate dasiglucagon

Read the full 148 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE